小摩：予Insmed(INSM.US)等六只大型生物科技股“增持”评级

智通财经网2023-11-27

智通财经APP获悉，摩根大通在最近的一份报告中恢复了对15只大型生物科技股的评级。具体来看，该行予Insmed(INSM.US)、Denali(DNLI.US)、Immunocore(IMCR.US)、Crinetics(CRNX.US)、Mirum(MIRM.US)和BioCryst(BCRX.US)“增持”评级，予Cervel Therapeutics (CERE.US)、Alkermes(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2386797831?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-11-27 08:16","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2386797831","market":"sh","top_or_hot":-1,"title":"小摩：予Insmed(INSM.US)等六只大型生物科技股“增持”评级","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，摩根大通在最近的一份报告中恢复了对15只大型生物科技股的评级。具体来看，该行予Insmed(INSM.US)、Denali(DNLI.US)、Immunocore(IMCR.US)、Crinetics(CRNX.US)、Mirum(MIRM.US)和BioCryst(BCRX.US)“增持”评级，予Cervel Therapeutics (CERE.US)、Alkermes(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1029339.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>小摩：予Insmed(INSM.US)等六只大型生物科技股“增持”评级</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n小摩：予Insmed(INSM.US)等六只大型生物科技股“增持”评级\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-27 08:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1029339.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，摩根大通在最近的一份报告中恢复了对15只大型生物科技股的评级。具体来看，该行予Insmed(INSM.US)、Denali(DNLI.US)、Immunocore(IMCR.US)、Crinetics(CRNX.US)、Mirum(MIRM.US)和BioCryst(BCRX.US)“增持”评级，予Cervel Therapeutics (CERE.US)、Alkermes(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1029339.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1029339.html","article_id":"2386797831","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2386797831","pubTimestamp":1701044183,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，摩根大通在最近的一份报告中恢复了对15只大型生物科技股的评级。具体来看，该行予Insmed、Denali、Immunocore、Crinetics、Mirum和BioCryst“增持”评级，予Cervel Therapeutics 、Alkermes、Novocure、Deciphera、Stoke和Esperion“中性”评级，予Amarin、Emergent BioSolutions和Nektar Therapeutics“减持”评级。对于Insmed，小摩认为，在近期研究更新的背景下、以及其对brensocatib治疗非囊性纤维化支气管扩张的ASPEN研究的“备受期待”的数据公布之前，该股预计将走高。在肿瘤药物Kimmtrak强势上市后，小摩同样看好Immunocore股票的上行空间。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"INSM":"Insmed"},"translate_title":"Xiaomo: Give Insmed (INSM.US) and other six large biotechnology stocks an \"overweight\" rating","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1},"content_text":"智通财经APP获悉，摩根大通在最近的一份报告中恢复了对15只大型生物科技股的评级。具体来看，该行予Insmed(INSM.US)、Denali(DNLI.US)、Immunocore(IMCR.US)、Crinetics(CRNX.US)、Mirum(MIRM.US)和BioCryst(BCRX.US)“增持”评级，予Cervel Therapeutics (CERE.US)、Alkermes(ALKS.US)、Novocure(NVCR.US)、Deciphera(DCPH.US)、Stoke(STOK.US)和Esperion(ESPR.US)“中性”评级，予Amarin(AMRN.US)、Emergent BioSolutions(EBS.US)和Nektar Therapeutics(NKTR.US)“减持”评级。对于Insmed，小摩认为，在近期研究更新的背景下、以及其对brensocatib治疗非囊性纤维化支气管扩张的ASPEN研究的“备受期待”的数据公布之前，该股预计将走高。该行对该股的目标价为36美元。与此同时，小摩认为，Denali的股票可能会在2025年的几次数据公布之前走高，其ALS候选药物DNL788预计将在2024年上半年公布第二阶段数据。该行从该公司的管道药物中看到了“创造价值的多种途径”，且“仍处于潜在价值的早期阶段”。该行对该股的目标价为28美元。在肿瘤药物Kimmtrak强势上市后，小摩同样看好Immunocore股票的上行空间。该行强调了PRAME和一个“去风险”技术平台潜在的“高价值管道机会”，并将对该股的目标价定为60美元。对于Crinetics，小摩表示，该公司未来12个月可能受益于集中催化剂，在其主要候选药物paltustine的“强劲”三期数据公布后，该行看好该公司，对其目标价为35美元。小摩表示，Mirum旗下Livmarli是一个“有吸引力的机会”，支撑该股的估值，且其候选药物volixibat的临床风险降低推动了进一步的上涨潜力。小摩还看好BioCryst，称该公司的药物Orladeyo是“该股的关键价值驱动因素”，其广泛的产品线代表着上涨潜力。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2386797831"}